[Case #2. High-grade B-cell lymphoma with 11q aberration: A case report]

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• High-grade B-cell lymphoma with 11q aberration (HGBL-11q) is a new classification entity (2022 WHO).
• HGBL-11q shares morphological and immunohistochemical features with Burkitt lymphoma.
• Distinct molecular features differentiate HGBL-11q from Burkitt lymphoma.

Purpose of the Study:

• To define the key molecular and clinical characteristics of HGBL-11q.
• To differentiate HGBL-11q from Burkitt lymphoma based on genetic aberrations.
• To describe the epidemiological and clinical presentation of HGBL-11q.

Main Methods:

• Analysis of cytogenetic and molecular data to identify chromosomal abnormalities.
• Morphological and immunohistochemical assessment of lymphoma tissues.
• Clinical data review including patient demographics, symptoms, and disease involvement.

Main Results:

• HGBL-11q is characterized by 11q gain/loss patterns, lacking MYC rearrangements.
• Burkitt lymphoma is defined by MYC rearrangements involving immunoglobulin genes.
• The condition predominantly affects pediatric and adolescent populations, often without B symptoms.
• Common sites include head and neck lymph nodes (60-70%) and gastrointestinal tract (30-40%).

Conclusions:

• HGBL-11q represents a unique lymphoma entity defined by specific chromosomal aberrations.
• Accurate molecular diagnosis is crucial for distinguishing HGBL-11q from Burkitt lymphoma.
• Understanding HGBL-11q's clinical presentation aids in diagnosis and management of this rare pediatric lymphoma.